Clinical efficacy of pemirolast potassium at the time of massive cedar pollen attacks in 1995

• Published in: OTOLOGIA FUKUOKA Vol. 44; no. 1; pp. 73 - 83
• Main Authors: YAMAMOTO, Masahiko, TANIKAWA, Hirokazu, SHIMADA, Akiko, NUMATA, Tsutomu, OHARA, Keikou, KANDA, Takashi, CHO, Satoru, YAMAKOSHI, Takayuki, FUJITA, Yosuke, MIURA, Takumi, WADA, Ken, ANDO, Ichiro, YONEMOTO, Masaaki, HAMANO, Nanako, HASEGAWA, Masaya, KONNO, Akiyoshi, SOU, Nagamoto
• Format: Journal Article
• Language: Japanese
• Published: JIBI TO RINSHO KAI 20.01.1998
• Subjects: スギ花粉症; ペミロラストカリウム; 抗アレルギー薬
• ISSN: 0447-7227; 2185-1034
• DOI: 10.11334/jibi1954.44.1_73

In 1995, when the cedar pollen level was unusually high in Japan, 65 cedar pollen allergy patients were divided into two groups using the envelope method. One group consisted of 27 subjects who received an oral H1 antagonist and topical steroid, while the other group consisted of 38 subjects who received Alegysal in addition to these drugs. The nasal symptoms, degree of interference with the activities of daily living, and rhinoscopic findings were determined before treatment and at 2 and 4 weeks after treatment. The efficacy leveled off 2 weeks after treatment in the control group, while in the Alegysal group, the symptoms and findings showed a tendency to further improve until 4 weeks after treatment. Interference with the activities of daily living was significantly less marked in the Alegysal group than in the control group 4 weeks after treatment. The patients' subjective evaluation of the treatment's efficacy was “excellent” in 47% and “excellent” or “good” in 95%, respectively, in the Alegysal group, while the same evalutions were 26% and 78%, respectively, in the control group. The U-test showed significant differences between the two groups (p<0.05). Adverse reaction occurred in only 2 of 49 patients (4%), but no serious adverse reaction was obseved. These findings indicate that co-administration of Alegysal with oral H1 antagonists and topical steroids is therefore an effective treatment for patients with severe Japanese cedar pollinosis.